Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ali Dohan

Internal Medicine Indianapolis, IN Medical Doctor

NPI 1558457432 CMS profile 342453

1250 E County Line Road, Suite 8, Indianapolis, IN 46227

Open in the dashboard

General payments

$10,116

640 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ali Dohan of Indianapolis, IN is reported in the CMS Open Payments database as having received $10,116 across 640 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $569 29
2024 General $880 38
2023 General $876 56
2022 General $1,501 97
2021 General $2,437 159
2020 General $1,760 115
2019 General $2,093 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Dohan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Ali Dohan were reported at $569. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Ali Dohan Internal Medicine median Middle half National median
2019 $2,093 $159 $48–$570 $163
2020 $1,760 $119 $33–$402 $114
2021 $2,437 $135 $37–$521 $132
2022 $1,501 $141 $42–$496 $149
2023 $876 $149 $45–$519 $160
2024 $880 $154 $47–$537 $164
2025 $569 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,431 113 payments
  2. GlaxoSmithKline, LLC. $1,218 66 payments
  3. AstraZeneca Pharmaceuticals LP $1,070 61 payments
  4. AbbVie, Inc. $894 72 payments
  5. Lilly USA, LLC $777 51 payments
  6. Amgen Inc. $740 36 payments
  7. Novartis Pharmaceuticals Corporation $450 28 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $359 22 payments
  9. Kowa Pharmaceuticals America, Inc. $315 23 payments
  10. E.R. Squibb & Sons, L.L.C. $315 18 payments
  11. Other $2,548 150 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,109 638 payments
  2. Education $7 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $939 45 payments
  2. Ozempic $754 60 payments
  3. FARXIGA $575 30 payments
  4. RYBELSUS $564 41 payments
  5. Repatha $473 25 payments
  6. LINZESS $442 34 payments
  7. JARDIANCE Diabetes $417 30 payments
  8. VRAYLAR $410 40 payments
  9. JARDIANCE Diabetes $359 22 payments
  10. ENTRESTO $355 22 payments
  11. Other $7,654 479 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 114 drugs

Part D claims

6,190

Median for Internal Medicine: 777

Drug cost

$649,455

Median for Internal Medicine: $73,373

Branded share of claims

25.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 72 $92,742
Mounjaro Tirzepatide Brand 77 $90,582
Ozempic Semaglutide Brand 59 $73,307
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 92 $69,553
Eliquis Apixaban Brand 62 $56,638
Entresto Sacubitril/Valsartan Brand 37 $41,870
Trulicity Dulaglutide Brand 34 $34,141
Linzess Linaclotide Brand 45 $31,620
Xarelto Rivaroxaban Brand 22 $23,610
Farxiga Dapagliflozin Propanediol Brand 22 $23,564

The 10 drugs with the highest cost, of 114 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$42,101

Medicare's payments for the services billed

Medicare patients

79

Average age 73

Services billed

798

42 women, 37 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 47%
Ischemic heart disease 33%
Depression 33%
Chronic kidney disease 27%
COPD 24%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $124
$124 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $109
$109 22 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $71
$71 92 —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $67
$67 18 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

640 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record